Scotiabank raised the firm’s price target on Castle Biosciences (CSTL) to $44 from $37 and keeps an Outperform rating on the shares. The company’s Q3 results beat consensus expectations and raised its FY24 revenue guidance again, the analyst tells investors. TissueCypher ramp continues to outpace the firm’s expectations and the company is also on target to provide an update for its inflammatory disease pipeline by the end of 2024, the firm adds.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Faces Financial Strain Amid 2024 Loan Covenant Restrictions
- Castle Biosciences price target raised to $45 from $40 at BTIG
- Castle Biosciences price target raised to $40 from $34 at Lake Street
- Castle Biosciences price target raised to $39 from $37 at Baird
- Castle Biosciences price target raised to $36 from $28 at KeyBanc